Loading organizations...
SOV Therapeutics develops oral testosterone replacement therapies for adult men. Its core product employs a proprietary T-replacement therapy utilizing testosterone undecanoate. This unique approach enables absorption via the intestinal lymphatic system, bypassing difficulties with portal vein delivery. This technical innovation provides a more efficient and effective oral delivery mechanism for therapeutic treatment.
Om Dhingra founded SOV Therapeutics in 2009. He recognized physiological challenges in existing oral testosterone delivery methods. Dhingra aimed to create a reliable oral administration, developing their distinct pro-drug formulation. This innovative system was designed to address a critical medical need, securing initial capital to advance its development.
SOV Therapeutics targets adult men requiring testosterone replacement therapy. The company's vision centered on offering convenient, physiologically optimized oral treatment for this population. By enhancing testosterone absorption and delivery, SOV Therapeutics sought to improve quality of life for men needing hormonal regulation, envisioning a future with more effective and accessible options.
SOV has 2 tracked investments across 1 company. The latest tracked deal is $8.0M Series A in Veremark in July 2022.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Jul 1, 2022 | Veremark | $8.0M Series A | Stage 2 Capital | ACF Investors, RED Beard Ventures, RTP Global, Samaipata, Target Global, Charles Delingpole, Triple Point Ventures, Vulpes |
| Sep 1, 2021 | Veremark | $3.0M Seed | — | ACF Investors, Angel Invest, Antler, Boost Capital Partners, Goodwater Capital, Passion Capital, RED Beard Ventures, Sequel, Social Capital, Sound Ventures, Speedinvest, The HIT Forge, Daniel Cardenas Clark, Desigan Chinniah, Marc Benioff, Mark Cuban, Charles Delingpole, Drew Austin, Prasanna Sankar, Rika Christanto, Triple Point Ventures, Vulpes Investment Management |
